David Perry, DO
Cardiovascular Disease · Provo, UTNPI 1295029528
Payments from drug & device makers
Across 447 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Pfizer$1K
- Amgen$667
- Actelion Pharmaceuticals US, Inc.$626
- Johnson & Johnson$528
- Boston Scientific$519
- plus $3K from 35 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,361 |
| Pfizer | 109 | $1,127 |
| Amgen | 34 | $667 |
| Actelion Pharmaceuticals US, Inc. | 42 | $626 |
| Johnson & Johnson | 34 | $528 |
| Boston Scientific | 26 | $519 |
| Novartis | 29 | $493 |
| Merck | 25 | $467 |
| Boehringer Ingelheim | 27 | $438 |
| E.r. Squibb & Sons, L.L.C. | 17 | $260 |
| AstraZeneca | 15 | $213 |
| Lantheus Medical Imaging, Inc. | 6 | $209 |
| Amarin Pharma, Inc. | 13 | $167 |
| Alnylam Pharmaceuticals Inc. | 6 | $111 |
| United Therapeutics Corporation | 5 | $88 |
| Baxter Healthcare | 2 | $84 |
| Bridgebio Pharma, Inc. | 3 | $80 |
| Heartflow, Inc. | 2 | $71 |
| Gilead | 5 | $68 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $62 |
| Impulse Dynamics (USA) Inc. | 2 | $50 |
| Masimo Corporation | 3 | $44 |
| Inspire Medical Systems, Inc. | 3 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Bayer | 2 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Cardinal Health 200 LLC | 1 | $19 |
| Medtronic | 1 | $18 |
| Organon | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Teleflex LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Analog Devices Inc. | 1 | $14 |
| Biotronik Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $11 |
How this compares
$8,093 in reported general payments places this provider in the 65th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Provo
- Vlad RadulescuProvo$216K
- Marvin AllenProvo$9K
- Stephen WilkinsonProvo$8K
- Phanindra AntharamProvo$6K
- Hussein DaoudProvo$3K
- John RyanSalt Lake City$4.2M
- Brian WhisenantMurray$3.4M
- Jeffrey AndersonSalt Lake City$1.7M
- Divya Ratan VermaMurray$1.1M
- Robert FowlesSalt Lake City$611K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.